Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Eckert & Ziegler Strahlen- und Medizintechnik AG, DE0005659700

Eckert & Ziegler Strahlen- und Medizintechnik AG, DE0005659700

16.04.2021 - 11:04:40

???????Eckert & Ziegler Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM

Berlin, 16 April 2021 - Eckert & Ziegler Strahlen- und Medizintechnik AG today acquired several share packages from the founders of the drug developer PENTIXAPHARM GmbH. Together with another internal share transfer, Eckert & Ziegler AG will directly hold a total of about 83% of the shares in the W?rzburg-based company as of closing of the transactions. The total cost for the three share packages amount to approximately EUR 30 million. About a quarter of the purchase price payments will be made in cash, the remainder in shares of Eckert & Ziegler AG, which the seller has committed to hold at least until the date at which an advanced clinical trial approval is expected. The management of PENTIXAPHARM, which holds the remaining 17% of PENTIXAPHARM shares, has been granted additional options to sell its remaining shares.? For enquiries please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-R?ssle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

Information and Explanation of the Issuer to this News:

PENTIXAPHARM is developing a radiopharmaceutical combination product against lymphoma and a number of related tumors. Depending on whether chelated with Gallium-68 or Yttrium-90, the product will be able to be used both for the diagnosis and the therapy of cancer. For the lead diagnostic PENTIXAFOR, PENTIXAPHARM recently received the green light for advanced clinical trials from the European Medicines Agency in a form of preliminary notification. The management of PENTIXAPHARM expects that it will be able to go through the approval process in approximately three years. Eckert & Ziegler AG intends to raise funds for the approval process through further investments in the aftermath of its acquisition of PENTIXAPHARM.

16-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-R?ssle-Str.10 13125 Berlin

Germany Phone: +49 30 941084-138 Fax: +49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1185688 ? End of Announcement DGAP News Service

1185688??16-Apr-2021?CET/CEST

@ dgap.de